bioMérieux - Information on 2011 Sales Objective

The deteriorating market conditions are impacting the acceleration of sales expected at the end of the year.

The Group, which has close to half of its sales in Western Europe, is faced with a slowdown of the region’s economy and budget austerity measures in Southern Europe. However, sales remain solid in North America and growth is dynamic in the Emerging 7*. Clinical Microbiology, which accounts for more than 50% of bioMérieux’s sales, continues to grow faster than the market and to gain market share**.

bioMérieux anticipates a strong month of December, which would make it possible to forecast 2011 organic sales growth of 4.5%. However, in light of the sales growth recorded at the end of November and of uncertainties about how market conditions will evolve, this growth could be difficult to reach and therefore, 2011 organic growth could be between 3.5% and 4.5%. Including the recent acquisitions of AES Laboratoire and ARGENE, overall growth for 2011 could be between 5.5% and 6.5%, at constant exchange rates.

“bioMérieux is facing an economic environment in Western Europe that is deteriorating more rapidly and dampening our growth. However, our teams are focused more than ever on reaching our objectives and our broad international footprint and the confirmed success of our core business, clinical microbiology, are significant assets,” stated Jean-Luc Bélingard, Chairman and Chief Executive Officer.

Investor Calendar

January 24, 2012: Fourth-quarter 2011 sales - After the close of trading

The above forward-looking statements are based, entirely or partially, on assessments or judgments that may change or be modified, due to uncertainties and risks related to the Company's economic, financial, regulatory and competitive environment, notably those described in the 2010 Registration Document. Accordingly, the Company cannot give any assurance nor make any representation as to whether the above objectives will be met. The Company does not undertake to update or otherwise revise any forecasts or objectives presented herein, except in compliance with the disclosure obligations applicable to companies whose shares are listed on a stock exchange.

* Brazil, China, India, Indonesia, Mexico, Russia and Turkey
** Based on bioMérieux estimates

About bioMérieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2010, revenues reached €1.357 billion with 87% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM - ISIN: FR0010096479).

Other information can be found at www.biomerieux.com.

Contacts

Investor Relations

bioMerieux
Isabelle Tongio
Tel: + 33 4 78 87 22 37
investor.relations@biomerieux.com

Media Relations

bioMerieux
Koren Wolmna-Tardy
Tel: + 33 4 78 87 20 08
media@biomerieux.com

Image Sept
Laurence Heilbronn
Tel: + 33 1 53 70 74 64
lheilbronn@image7.fr

Albane de la Tour d'Artaise
Tel: + 33 1 53 70 74 84
adelatour@image7.fr